Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 175 results for "erbitux"

4 Drug Stocks Poised to Surprise this Earnings Season

In the biotech sector, investor focus will now shift from the annual J.P. Morgan Healthcare Conference to the Q4 earnings season. The sector has faced challenging conditions for more than a year due to media and political focus on steep drug ..., 1 day ago

5 images for erbitux, 2 days ago
FierceBiotech, 1 week ago
pharmaphorum, 2 months ago
Pharmafile, 6 months ago
Nasdaq, 6 months ago
American Banking News

What Eli Lilly Gets With CoLucid Acquisition

Source: ThinkstockEli Lilly and Co. (NYSE: LLY) has announced it has reached an agreement to acquire CoLucid Pharmaceuticals Inc. (NASDAQ: CLCD) in an all-cash transaction for $46.50 per share, or about $960 million. This not only will enhance Eli ...
 24/7 Wall St4 days ago Zacks Investment Research Downgrades Eli Lilly and Co. (LLY) to Sell  American Banking News1 month ago Eli Lilly and Co. (LLY) Downgraded to Sell at Zacks Investment Research  Mideast Time1 month ago

Surgery vs Chemoradiation in Head and Neck Cancer

The first large-scale analysis to compare upfront surgery to definitive chemoradiation (CRT) in patients with human papilloma virus (HPV)-negative oropharyngeal squamous cell cancer (OPSCC) found no difference in overall survival between the two ...
 Dermatology Online Journal6 days ago

Deal may have kept life-saving drug off market

With Donald Trump's threats to rein in drug pricing , what would he make of the Syprine situation? A drug called Syprine has played a starring role in the collapse of Valeant ( VRX ), the rogue pharmaceutical company that lost 90% of its value ...
 Yahoo! News1 week ago The strange deal 2 drug makers had over a medicine with a skyrocketing price  Yahoo! Finance UK and Ireland1 week ago

Further reductions in medicine prices

Helena Dalli, Minister for Social Dialogue, Consumer Affairs and Civil Liberties, recently announced the reduction in price of 29 medicines and the introduction of 10 new generic medicines which patients can purchase instead of the original medicine ...
 Times of Malta1 week ago

Kitov buys program designed to stop cancer drug resistance

Kitov Pharmaceuticals has bought a 56% stake in TyrNovo to take control of a cancer program. The focal point of the deal is NT219, an IRS-1/2-targeting drug designed to improve the efficacy of other cancer therapies by stopping tumors from ...
 FierceBiotech1 week ago

Banner, Speculation

Few people today call themselves speculators. The word is too loaded. Instead, they are traders, hedge fund managers, and the like. But, whatever they call themselves, they are speculators. They're the ones people blame for everything from business ...
 Seeking Alpha1 week ago Book Review: Speculation  Investing.com3 weeks ago
Colorectal Cancer Association of Canada

(Jan-05) - The Next Frontier: The Promise of Immunotherapy in Gastrointestinal Cancers

In the oncology world, gastrointestinal cancers may be the next in line to realize the promise of immunotherapy. BY ARLENE WEINTRAUB MARY ANN MACHOL, diagnosed with stage 4 colorectal cancer, has responded well to immunotherapy. [PHOTO BY ...
 Colorectal Cancer Association of Canada1 week ago Checkpoint Inhibitors Expected to Play a Growing Role in Head and Neck Cancer Treatment  CURE Magazine2 weeks ago Examining the Future of Immunotherapy in Head and Neck Cancer  CURE Magazine2 months ago

JPMorgan Makes Big Changes to US Analyst Focus List for January

That sure didn't take long. And it probably should come as no surprise that many of the top firms we cover here at 24/7 Wall St. are already tweaking their high conviction stock lists for 2017. They are trying to take into account macro changes that ...
 Yahoo! Finance1 week ago Merrill Lynch Makes Huge Changes by Removing 2 Blue Chips From US 1 List  24/7 Wall St1 month ago

3SBio Appoints As President Of Research & Development And Chief Scientific Officer

SHENYANG, China , Jan. 9, 2017 /PRNewswire/ -- 3SBio Inc., (HKEX:1530) ("3SBio" and together with its subsidiaries the "3SBio Group") is pleased to announce that Zhenping Zhu , MD, PhD, has joined 3SBio as its new President of Research & ...
 BioSpace1 week ago 3SBio Inc. Appoints Dr. Zhenping Zhu as President of Research & Development and Chief Scientific Officer  Stockwatch1 week ago 3SBio Inc Appoints Dr Zhenping Zhu as President of Research Development and Chief Scientific Officer  Pharma Focus Asia1 week ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less